Itemaren erregistro erraza erakusten du

dc.contributor.authorTurajlic, Samra
dc.contributor.authorXu, Hang
dc.contributor.authorLitchfield, Kevin
dc.contributor.authorRowan, Andrew
dc.contributor.authorHorswell, Stuart
dc.contributor.authorChambers, Tim
dc.contributor.authorO'Brien, Tim
dc.contributor.authorLópez Fernández de Villaverde, José Ignacio ORCID
dc.contributor.authorWatkins, Thomas B. K.
dc.contributor.authorNicol, David
dc.contributor.authorStares, Mark
dc.contributor.authorChallacombe, Ben
dc.contributor.authorHazell, Steve
dc.contributor.authorChandra, Ashish
dc.contributor.authorMitchell, Thomas J.
dc.contributor.authorAu, Lewis
dc.contributor.authorEichler-Jonsson, Claudia
dc.contributor.authorJabbar, Faiz
dc.contributor.authorSoultati, Aspasia
dc.contributor.authorChowdhury, Simon
dc.contributor.authorRudman, Sarah
dc.contributor.authorLynch, Joanna
dc.contributor.authorArchana Sinduri, Fernando
dc.contributor.authorStamp, Gordon
dc.contributor.authorNye, Emma
dc.contributor.authorStewart, Aengus
dc.contributor.authorXing, Wei
dc.contributor.authorSmith, Jonathan C.
dc.contributor.authorEscudero, Mickael
dc.contributor.authorHuffman, Adam
dc.contributor.authorMatthews, Nik
dc.contributor.authorElgar, Greg
dc.contributor.authorPhillimore, Ben
dc.contributor.authorCosta, Marta
dc.contributor.authorBegum, Sharmin
dc.contributor.authorWard, Sophia
dc.contributor.authorSalm, Max
dc.contributor.authorBoeing, Stefan
dc.contributor.authorFisher, Rosalie
dc.contributor.authorSpain, Lavinia
dc.contributor.authorNavas, Carolina
dc.contributor.authorGronroos, Eva
dc.contributor.authorHobor, Sebastijan
dc.contributor.authorSharma, Sarkhara
dc.contributor.authorAurangzeb, Ismaeel
dc.contributor.authorLall, Sharanpreet
dc.contributor.authorPolson, Alexander
dc.contributor.authorVaria, Mary
dc.contributor.authorHorsfield, Catherine
dc.contributor.authorFotiadis, Nicos
dc.contributor.authorPickering, Lisa
dc.contributor.authorSchwarz, Roland F.
dc.contributor.authorSilva, Bruno
dc.contributor.authorHerrero, Javier
dc.contributor.authorLuscombe, Nick M.
dc.contributor.authorJamal-Hanjani, Mariam
dc.contributor.authorRosenthal, Rachel
dc.contributor.authorBirkbak, Nicolai J.
dc.contributor.authorWilson, Gareth A.
dc.contributor.authorPipek, Orsolya
dc.contributor.authorRibli, Dezso
dc.contributor.authorKrzystanek, Marcin
dc.contributor.authorCsabai, Istvan
dc.contributor.authorSzállási, Zoltán
dc.contributor.authorGore, Martin E.
dc.contributor.authorMcGranahan, Nicholas
dc.contributor.authorVan Loo, Peter
dc.contributor.authorCampbell, Peter
dc.contributor.authorLarkin, James
dc.contributor.authorSwanton, Charles
dc.date.accessioned2018-12-13T12:36:30Z
dc.date.available2018-12-13T12:36:30Z
dc.date.issued2018-04-19
dc.identifier.citationCell 173(3) : 595-610 (2018)es_ES
dc.identifier.issn0092-8674
dc.identifier.issn1097-4172
dc.identifier.urihttp://hdl.handle.net/10810/30325
dc.description.abstractThe evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, TRACERx Renal. We observe up to 30 driver events per tumor and show that subclonal diversification is associated with known prognostic parameters. By resolving the patterns of driver event ordering, co-occurrence, and mutual exclusivity at clone level, we show the deterministic nature of clonal evolution. ccRCC can be grouped into seven evolutionary subtypes, ranging from tumors characterized by early fixation of multiple mutational and copy number drivers and rapid metastases to highly branched tumors with > 10 subclonal drivers and extensive parallel evolution associated with attenuated progression. We identify genetic diversity and chromosomal complexity as determinants of patient outcome. Our insights reconcile the variable clinical behavior of ccRCC and suggest evolutionary potential as a biomarker for both intervention and surveillance.es_ES
dc.description.sponsorshipWe thank Aida Murra, Naheed Shaikh, Justine Korteweg, Jeremy Tai, Eleanor Carlyle, Leonora Conneely, KimEdmonds, Karla Lingard, Karen O'Meara, Helen Breeze, Sarah Sarker, Lesley Cooper, Linda Shephard, Susie Slater, and Catherine Rogers for study support. We thank the patients and their families. S.T. and H.X. are funded by Cancer Research UK (CRUK) (C50947/A18176). S.T., T.C., J.L., and M.G. are funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital and Institute of Cancer Research (A109). J.I.L. is funded by the Ministerio de Economia y Competitividad (MINECO, SAF2016-79847-R). M.S., A.S., J. Lynch, R.F., L.A., and L.S. are funded by the Royal Marsden Cancer Charity. K.L. is funded by UK Medical Research Council (MR/P014712/1). T.B.K.W. is funded by the European Union Seventh Framework Programme (FP7-People-2013-ITN). M.J.-H. is funded by the NIHR. N.M.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation's support towards the establishment of The Francis Crick Institute. N.M.L. is additionally funded by a Wellcome Trust Joint Investigator Award (103760/Z/14/Z) and the MRC eMedLab Medical Bioinformatics Infrastructure Award (MR/L016311/1). M.K. is funded by the Danish Cancer Society grant (R90-A6213). P.C. is funded by the Wellcome Trust (WT088340MA). N.M. receives funding from CRUK, Rosetrees, and the NIHR BRC at University College London Hospitals. C.S. is a Royal Society Napier Research Professor. C.S. is funded by Cancer Research UK (TRACERx and CRUK Cancer Immunotherapy Catalyst Network), the CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), the Rosetrees and Stoneygate Trusts, NovoNordisk Foundation (THESEUS), Marie Curie Network PloidyNet, the NIHR BRC at University College London Hospitals, and the CRUK University College London Experimental Cancer Medicine Centre. C.S., O.P., D.R., I.C., and Z.S. are funded by NovoNordisk Foundation (16584). O.P., D.R., and I.C. are funded by the National Research, Development and Innovation Office of Hungary (NVKP_16-1-20160004). This work was supported by CRUK (Clinical Scientist Fellowship to S.T., C50947/A18176), The Francis Crick Institute, which receives its core funding from Cancer Reseach UK (FC010110), the UK Medical Research Council (FC010110), the Wellcome Trust (FC010110), and NIHR BRC at the Royal Marsden Hospital and Institute of Cancer Research (A109). High-performance computing was supported by eMedLab. The results published here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.es_ES
dc.language.isoenges_ES
dc.publisherCell Presses_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/SAF2016-79847-Res_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcopy-number alterationses_ES
dc.subjectcell carcinomaes_ES
dc.subjectrhabdoid differentiationes_ES
dc.subjectinternational societyes_ES
dc.subjectactive surveillancees_ES
dc.subjectdriver mutationes_ES
dc.subjectsequencing dataes_ES
dc.subjectkidney canceres_ES
dc.subjectBAP1es_ES
dc.subjectgenees_ES
dc.titleDeterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderAttribution 4.0 International (CC BY 4.0) You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0092867418303751?via%3Dihub#!es_ES
dc.identifier.doi10.1016/j.cell.2018.03.043
dc.departamentoesEspecialidades médico-quirúrgicases_ES
dc.departamentoeuMedikuntza eta kirurgia espezialitateakes_ES


Item honetako fitxategiak

Thumbnail
Thumbnail

Item hau honako bilduma honetan/hauetan agertzen da

Itemaren erregistro erraza erakusten du

Attribution 4.0 International (CC BY 4.0)
You are free to: 
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Bestelakorik adierazi ezean, itemaren baimena horrela deskribatzen da:Attribution 4.0 International (CC BY 4.0) You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially.